子宫颈高级别上皮内病变切除性治疗围手术期HPV疫苗应用的中国专家共识(2025版)  

Chinese Expert Consensus on Application of HPV Vaccine in Perioperative Treatment of High-Grade Cervical Intraepithelial Neoplasia(2025 Edition)

作　　者：中国妇幼健康研究会子宫颈癌防控研究专业委员会 吴绪峰[2] 王临虹[3] 毕蕙[4] 赵方辉[5] 陈飞[6] 刘军[7] 李明珠[8] 郭玉琳 Cervical Cancer Prevention and Control Research Professional Committee of Chinese Association for Maternal and Child Health Study;WU Xufeng;WANG Linhong

机构地区：[1]不详 [2]湖北省妇幼保健院 [3]中国疾病预防控制中心 [4]北京大学第一医院 [5]中国医学科学院肿瘤医院 [6]北京协和医院 [7]首都医科大学附属北京朝阳医院 [8]北京大学人民医院

出　　处：《肿瘤防治研究》2025年第3期177-184,共8页Cancer Research on Prevention and Treatment

摘　　要：在接受切除性治疗的子宫颈高级别鳞状上皮内病变(HSIL)女性中,接种HPV疫苗可能会减少术后疾病的复发风险,但目前国内的研究数据较少,且缺乏明确的应用指南。中国妇幼健康研究会子宫颈癌防控研究专委会组织本领域的相关专家,在我国特有的临床实践背景下组织制订了本部共识。本共识推荐适龄、无禁忌证、经组织病理学证实的子宫颈HSIL且接受了切除性治疗的女性接种预防性HPV疫苗,以降低其复发风险,接种时间推荐在HSIL确诊后或完成切除性治疗后尽早接种,接种程序推荐三剂次。对于子宫颈HSIL治疗前已经接种HPV疫苗的女性,切除性治疗后无需再次接种。对于子宫颈HSIL切除性治疗后女性,即使接种了HPV疫苗,仍应按治疗后管理指南定期进行随访,接种疫苗不能替代常规随访。In women with high-grade squamous intraepithelial lesion(HSIL)undergoing excision therapy,vaccination with human papillomavirus(HPV)vaccine may reduce the risk of postoperative recurrence.However,research data and clear application guidelines are currently limited in China.The Cervical Cancer Prevention and Control Research Committee of the China Maternal and Child Health Research Association gathered a team of relevant experts to develop the consensus based on the characteristics of clinical practice in China.This expert consensus suggests that women of appropriate age,without contraindications,with histopathological confirmation of HSIL,and who underwent excision treatment should receive a prophylactic HPV vaccine to reduce the risk of recurrence.The recommended vaccination time is as early as possible after HSIL diagnosis or after resection treatment,and the recommended vaccination procedure is three doses.For women who have already received an HPV vaccine before treatment,there is no need to receive again after excision therapy.For women who underwent resection treatment,even if they have received HPV vaccines,regular follow-up should still be conducted in accordance with the post-treatment management guidelines.Vaccination cannot replace routine follow-up.

关 键 词：子宫颈癌 高级别鳞状上皮内病变 切除性治疗 复发 HPV疫苗 共识 

分 类 号：R737.33[医药卫生—肿瘤]